Genexine Inc Cash Flow-to-Debt Ratio
Genexine Inc cash flow-to-debt ratio. Genexine Inc (095700) has a Cash Flow-to-Debt Ratio of -0.03x as of September 2025, meaning its operating cash flow of ₩-2.97 Billion could theoretically repay 0% of its total liabilities (₩106.21 Billion) in one year. Check how high is Genexine Inc's earnings quality to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Genexine Inc (2009–2024)
Cash flow-to-debt ratio of Genexine Inc from 2009 to 2024. Historical debt coverage capacity for Genexine Inc across 14 annual periods. Check Genexine Inc total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.
Genexine Inc Cash Flow-to-Debt Ratio by Year (2009–2024)
Genexine Inc cash flow-to-debt ratio by year from 2009 to 2024. Year-by-year debt coverage analysis for Genexine Inc. For the full cash flow conversion analysis, see 095700 operating cash flow.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.02x | ₩-1.65 Billion | ₩83.36 Billion | ▲ +95.9% |
| 2023 | -0.48x | ₩-38.05 Billion | ₩79.68 Billion | ▼ -35.1% |
| 2022 | -0.35x | ₩-39.80 Billion | ₩112.63 Billion | ▼ -230.3% |
| 2021 | -0.11x | ₩-12.75 Billion | ₩119.12 Billion | ▲ +71.1% |
| 2020 | -0.37x | ₩-22.69 Billion | ₩61.30 Billion | ▲ +45.4% |
| 2019 | -0.68x | ₩-41.57 Billion | ₩61.27 Billion | ▼ -83.7% |
| 2018 | -0.37x | ₩-20.05 Billion | ₩54.30 Billion | ▲ +62.1% |
| 2017 | -0.97x | ₩-26.10 Billion | ₩26.83 Billion | ▼ -96.5% |
| 2016 | -0.50x | ₩-14.10 Billion | ₩28.47 Billion | ▼ -392.5% |
| 2015 | -0.10x | ₩-1.64 Billion | ₩16.33 Billion | ▼ -205.8% |
| 2012 | 0.10x | ₩1.67 Billion | ₩17.55 Billion | ▲ +141.4% |
| 2011 | -0.23x | ₩-3.48 Billion | ₩15.14 Billion | ▲ +44.1% |
| 2010 | -0.41x | ₩-4.62 Billion | ₩11.24 Billion | ▼ -5091.0% |
| 2009 | 0.01x | ₩35.23 Million | ₩4.28 Billion | — |